相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
Peng Zhao et al.
ANNALS OF HEMATOLOGY (2022)
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
Daniel J. DeAngelo et al.
BLOOD (2022)
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
Roni Shouval et al.
BLOOD ADVANCES (2022)
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Esther Schuler et al.
ANNALS OF HEMATOLOGY (2021)
Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Qi Chen et al.
ANNALS OF HEMATOLOGY (2021)
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
Andreas Burchert
HAEMATOLOGICA (2021)
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
Andrius Zucenka et al.
ANNALS OF HEMATOLOGY (2021)
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success
Salvatore Fiorenza et al.
BIODRUGS (2021)
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Mohamed A. Kharfan-Dabaja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia
Hui Zhang et al.
CLINICAL CANCER RESEARCH (2021)
Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization
Anders Berglund et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Therapeutic cancer vaccine therapy for acute myeloid leukemia
Ming Wu et al.
IMMUNOTHERAPY (2021)
Hedgehog Signaling in Myeloid Malignancies
Ajay Abraham et al.
CANCERS (2021)
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Naval Daver et al.
LEUKEMIA (2021)
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Francesco Paolo Tambaro et al.
LEUKEMIA (2021)
Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
Rui Zhang et al.
CANCER MEDICINE (2021)
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori et al.
FRONTIERS IN ONCOLOGY (2021)
Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML
Firas El Chaer et al.
BLOOD ADVANCES (2021)
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Michael Heuser et al.
BLOOD ADVANCES (2021)
Epigenetic deregulation in myeloid malignancies
Hsuan-Ting Huang et al.
BLOOD (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success
Ilaria M. Michelozzi et al.
CANCERS (2021)
Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
Christian R. Schultze-Florey et al.
BLOOD ADVANCES (2021)
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia
Fevzi F. Yalniz et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Andreas Rank et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
Xavier Poire et al.
HAEMATOLOGICA (2020)
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
Bhagirathbhai Dholaria et al.
HAEMATOLOGICA (2020)
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Juan Eduardo Megias-Vericat et al.
BLOOD REVIEWS (2020)
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
Justin Loke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
CAR T cells: continuation in a revolution of immunotherapy
Anurag K Singh et al.
LANCET ONCOLOGY (2020)
Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells
Ivetta Danylesko et al.
LEUKEMIA (2020)
Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies
Paolo Bernasconi et al.
CANCERS (2020)
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
Tobias Herold et al.
LEUKEMIA (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
Francesca Patriarca et al.
FRONTIERS IN ONCOLOGY (2020)
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
Burak Kalin et al.
BLOOD ADVANCES (2020)
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
Lei Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
A. H. Wei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Betul Oran et al.
BLOOD ADVANCES (2020)
Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
Yunxiong Wei et al.
FRONTIERS IN ONCOLOGY (2020)
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia
Catriona Jamieson et al.
BLOOD CANCER DISCOVERY (2020)
Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors
Gursel Gunes et al.
BONE MARROW TRANSPLANTATION (2019)
Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia
Xiao-Ning Gao et al.
ANNALS OF HEMATOLOGY (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
Thierry Guillaume et al.
BONE MARROW TRANSPLANTATION (2019)
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Katherine D. Cummins et al.
HAEMATOLOGICA (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naive Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study
Jacqueline S. Garcia et al.
BLOOD (2019)
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Avichai Shimoni et al.
BLOOD CANCER JOURNAL (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
Robert Zeiser et al.
BLOOD (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
Ivana Gojo et al.
BLOOD (2019)
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Christina Rautenberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML
Sun Yao et al.
FRONTIERS IN ONCOLOGY (2019)
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
Thomas Schroeder et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT
Long Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
Bruno C. Medeiros et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation
Sebastian Sommer et al.
LEUKEMIA RESEARCH (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
ONCOLOGIST (2018)
Donor lymphocyte infusion in myeloid disorders
Selami Kocak Toprak
TRANSFUSION AND APHERESIS SCIENCE (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Thomas Schroeder et al.
ANNALS OF HEMATOLOGY (2018)
Evaluating measurable residual disease in acute myeloid leukemia
Farhad Ravandi et al.
BLOOD ADVANCES (2018)
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Katherine E. Lindblad et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect
Guillermo Orti et al.
EXPERIMENTAL HEMATOLOGY (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
Cornelis A. M. van Bergen et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Xavier Poire et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations
Nuria Mencia-Trinchant et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G. Bug et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making
Benjamin Tomlinson et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial
Janghee Woo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention
Xiao-Dong Mo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program
Toshihiro Miyamoto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
Charles Herbaux et al.
BLOOD (2017)
Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation
Z. Jedlickova et al.
BONE MARROW TRANSPLANTATION (2016)
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant
Ibraheem H. Motabi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico
Guillermo Orti et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
P. Tsirigotis et al.
BONE MARROW TRANSPLANTATION (2016)
Harnessing the immune system in acute myeloid leukaemia
Rebecca Austin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
Armin Ghobadi et al.
LEUKEMIA RESEARCH (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide
Tara M. Robinson et al.
SEMINARS IN HEMATOLOGY (2016)
Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
Li Xuan et al.
ONCOTARGET (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
MRD in AML: does it already guide therapy decision-making?
Gert Ossenkoppele et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
Maria Ilaria Del Principe et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Lynn Quek et al.
BLOOD ADVANCES (2016)
Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT)
Xavier Poire et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes
Christine N. Duncan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation
Jennifer E. Vaughn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study
Mohamed L. Sorror et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
J. Steinmann et al.
BONE MARROW TRANSPLANTATION (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2015)
Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
Xueyan Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
Y. Kong et al.
BLOOD CANCER JOURNAL (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
Jean-Emmanuel Bibault et al.
ONCOTARGET (2015)
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2015)
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
Gaku Oshikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation
L. Crucitti et al.
LEUKEMIA (2015)
Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Akiyoshi Takami et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation
Amer M. Zeidan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Ling Ge et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion
Pavan Bachireddy et al.
BLOOD (2014)
Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT
B. Tessoulin et al.
BONE MARROW TRANSPLANTATION (2014)
Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis
Nicolas Dulphy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia
Changcheng Zheng et al.
HEMATOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
Valentina Folgiero et al.
ONCOTARGET (2014)
Understanding anti-leukemia responses to donor lymphocyte infusion
Pavan Bachireddy et al.
ONCOIMMUNOLOGY (2014)
What is next generation sequencing?
Sam Behjati et al.
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION (2013)
Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes
Pramila Krishnamurthy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Finding the Sweet Spot for Donor Lymphocyte Infusions
Hyun Don Yun et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic. Stem Cell Transplantation
Gita Thanarajasingam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
Francis Mussai et al.
BLOOD (2013)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
MRD in AML: time for redefinition of CR?
Gert Ossenkoppele et al.
BLOOD (2013)
Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T- cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors
Chen-Hua Yan et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
Maximilian Christopeit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Transcriptional Regulation of IL-15 Expression during Hematopoiesis
Sara L. Colpitts et al.
JOURNAL OF IMMUNOLOGY (2013)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia
Hiroaki Shimizu et al.
LEUKEMIA RESEARCH (2013)
Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: A single-center analysis
Ji-Min Shi et al.
LEUKEMIA RESEARCH (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Minimal residual disease in acute myeloid leukaemia
Christopher S. Hourigan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
T. Maeda et al.
BLOOD CANCER JOURNAL (2013)
Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia
P. Rujkijyanont et al.
BLOOD CANCER JOURNAL (2013)
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse
Melhem Solh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT
Cristina Toffalori et al.
BLOOD (2012)
TRANSPLANTATION Azacitidine after allo-SCT: the good without the bad?
Mohamad Mohty et al.
BLOOD (2012)
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study
Roberto Raimondi et al.
BLOOD (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome
S. Yoshihara et al.
BONE MARROW TRANSPLANTATION (2012)
Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors
Chen-Hua Yan et al.
CLINICAL TRANSPLANTATION (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Genomic Loss of Mismatched Human Leukocyte Antigen and Leukemia Immune Escape From Haploidentical Graft-Versus-Leukemia
Luca Vago et al.
SEMINARS IN ONCOLOGY (2012)
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
Djordje Atanackovic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation
Eva Rettinger et al.
BLOOD (2011)
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death
Sara Serra et al.
BLOOD (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
L. S. Steelman et al.
LEUKEMIA (2011)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse
S. Thiant et al.
BONE MARROW TRANSPLANTATION (2010)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Impact of Minimal Residual Disease in CBFB-MYH11-Positive Acute Myeloid Leukemia
Andrea Corbacioglu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Gemtuzumab Ozogamicin Therapy for Isolated Extramedullary AML Relapse after Allogeneic Hematopoietic Stem-Cell Transplantation
Toshihiko Ando et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
Martin Bornhaeuser et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.
Luca Vago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
Vincent T. Ho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Current management and challenges of malignant disease in the CNS in paediatric leukaemia
Ching-Hon Pui et al.
LANCET ONCOLOGY (2008)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant
Taofeek Owonikoko et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
Alida Dominietto et al.
BLOOD (2007)
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt (R)) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study
Surasak Phuphanich et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
J. Cloos et al.
LEUKEMIA (2006)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Quantification of mRNA using real-time RT-PCR
Tania Nolan et al.
NATURE PROTOCOLS (2006)
Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation
A Takami et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome
H Chang et al.
LEUKEMIA RESEARCH (2004)
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome
D Cilloni et al.
ACTA HAEMATOLOGICA (2004)
Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms
F Maas et al.
LEUKEMIA (2003)
Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells
S Santourlidis et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
